Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.
Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.
The drugmaker says the therapeutic approach has a narrow treatment potential.
Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.
Roche also announced first-quarter sales shrank 1%.
The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
New data from the International Liver Congress in London this past weekend showed strong efficacy for Gilead's Sovaldi and AbbVie's combo regimen when paired with ribavirin.
Poland joins the list of countries in which GlaxoSmithKline is accused of misconduct. Meanwhile, bioequivalence issues have prompted the FDA to revoke its approval of GSK's Wellbutrin generic.
A London court knocked down two Roche/Genentech patents, making a clearer path for biosimilars of the breast cancer drug. The primary patent lapses in July.
Politico calls her departure an "everybody wins" situation.